Clinical Trials
101 trialsNCT07444905 2026-06-03
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
Tongji Hospital
Active not recruiting
NCT02379377 2026-06-02
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03257761 2026-06-01
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT05507632 2026-06-01
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Active not recruiting
NCT03186898 2026-05-29
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03896646 2026-05-22
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04792801 2026-05-22
TEP CARE
University Hospital, Lille
Active not recruiting
NCT06187961 2026-05-22
CCGLC-011
Tongji Hospital
Phase 2 Active not recruiting
NCT05546879 2026-05-20
Liver-NET1
University Hospital, Grenoble
Phase 1 Active not recruiting
NCT02984566 2026-05-19
TROG1703 LARK
University of Sydney
Phase NA Active not recruiting
NCT07581769 2026-05-14
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
First Affiliated Hospital, Sun Yat-Sen University
Active not recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT07573514 2026-05-07
BILIFLEX
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Active not recruiting
NCT01840592 2026-05-06
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03482102 2026-05-04
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06859840 2026-05-04
LEAF
Zhejiang University
Phase NA Active not recruiting
NCT02626312 2026-04-30
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06519721 2026-04-30
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
RenJi Hospital
Phase NA Active not recruiting
NCT07138885 2026-04-29
DRIVE-II
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06045975 2026-04-24
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting
NCT03655002 2026-04-20
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04605731 2026-04-20
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05666271 2026-04-13
Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes
Seoul National University Hospital
Active not recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT07493070 2026-03-25
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
Fujian Medical University Union Hospital
Phase NA Active not recruiting
NCT05128032 2026-03-19
PEDIR
Massachusetts General Hospital
Phase NA Active not recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06018857 2026-03-06
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation
The Cleveland Clinic
Active not recruiting
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07437859 2026-02-27
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
Peking Union Medical College Hospital
Active not recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05267080 2026-02-06
RESPECT
Cardiovascular and Interventional Radiological Society of Europe
Active not recruiting
NCT02967848 2026-02-05
LiverINSPECT
Royal North Shore Hospital
Active not recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07380633 2026-02-02
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Sun Yat-sen University
Phase 2 Active not recruiting
NCT01918683 2026-01-29
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT05113186 2026-01-29
LENVABLA
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04550481 2026-01-21
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
Phase 2 Active not recruiting
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06635694 2026-01-14
VIGILANT
Imperial College London
Active not recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02156739 2025-12-22
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06218511 2025-12-22
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
National Cancer Institute, Naples
Phase 1 Active not recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting